Group One Trading
FDMT icon

Group One Trading’s 4D Molecular Therapeutics FDMT Stock Holding History

Group One Trading’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$93.1K Buy
10,000
+5,900
+144% +$51.3K ﹤0.01% 4802
2025
Q4 		$30.8K Sell
4,100
-1,500
-27% -$15.2K ﹤0.01% 6004
2025
Q3 		$48.7K Buy
+5,600
New +$33.5K ﹤0.01% 5991
2025
Q2 		– Sell
-5,700
Closed -$18.4K – 8113
2025
Q1 		$18.4K Sell
5,700
-14,500
-72% -$68.3K ﹤0.01% 5871
2024
Q4 		$113K Buy
20,200
+19,100
+1,736% +$150K ﹤0.01% 4421
2024
Q3 		$11.9K Sell
1,100
-3,500
-76% -$58.1K ﹤0.01% 5522
2024
Q2 		$96.6K Sell
4,600
-1,000
-18% -$25.1K ﹤0.01% 3993
2024
Q1 		$178K Buy
+5,600
New +$143K ﹤0.01% 3657
2023
Q3 		– Sell
-1,000
Closed -$18.1K – 7826
2023
Q2 		$18.1K Buy
+1,000
New +$18.4K ﹤0.01% 6051
2022
Q1 		– Sell
-700
Closed -$15K – 8221
2021
Q4 		$15K Buy
+700
New +$17.2K ﹤0.01% 7133

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Group One Trading's FDMT Position: Q1 2026 in Review

Group One Trading opened a new position in 4D Molecular Therapeutics (FDMT) in Q1 2026: 1,998 shares worth $18.6K. The stake represents ﹤0.01% of the portfolio and ranks #6011 among its holdings. This is a return to the name: Group One Trading previously reported a position in FDMT as recently as Q4 2024.

Group One Trading first reported a position in FDMT in Q4 2021 and has held it in 8 quarters since. The position peaked at $74.8K in Q4 2023. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Group One Trading held 1,998 shares of 4D Molecular Therapeutics worth $18.6K as of Q1 2026.
  • 4D Molecular Therapeutics was a new Group One Trading position in Q1 2026.
  • 4D Molecular Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #6011 holding.
  • Group One Trading first reported a position in 4D Molecular Therapeutics in Q4 2021 and has held it in 8 quarters since.
  • Group One Trading's 4D Molecular Therapeutics position peaked at $74.8K in Q4 2023.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.